Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole,Mycoses

当前位置： X-MOL 学术 › Mycoses › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole
Mycoses ( IF 4.1 ) Pub Date : 2021-06-16 , DOI: 10.1111/myc.13336
Julia Jeck ₁ , Sebastian M Wingen-Heimann _{1,

2,

3} , Christian Thielscher ₃ , Anna Kron _{1,

2,

4,

5} , Jennifer Bonn ₁ , Florian Jakobs _{1,

2,

4} , Santiago Grau ₆ , David A Enoch ₇ , Christianne Micallef ₈ , Oliver A Cornely _{2,

5,

9,

10,

11} , Florian Kron _{1,

2,

3,

5}

Affiliation

VITIS Healthcare Group, Cologne, Germany.
Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
FOM University of Applied Sciences, Essen, Germany.
Network Genomic Medicine, University Hospital Cologne, Cologne, Germany.
Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology (CIO ABCD), University of Cologne, Cologne, Germany.
Pharmacy Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
Clinical Microbiology & Public Health Laboratory, National Infection Service, Public Health England, Addenbrookes Hospital, Cambridge, UK.
Pharmacy & Microbiology Departments, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Faculty of Medicine and University Hospital Cologne, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany.

Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of the innovative pharmaceutical isavuconazole in the inpatient setting in Germany (Bismarck-based healthcare system). Little is known about the reimbursement of innovative pharmaceuticals in the inpatient setting of Beveridge-based healthcare systems.

中文翻译：